The results of this multicenter study demonstrates that although follow up results are not provided, AFIP risk criteria seems to be more useful in prognostication for GISTs among the two systems. Objective: HER 2/neu overexpression or amplification is an important biomarker for identifying patients with intestinal-type gastric cancer who respond to therapy with Trastuzumab. Moreover, intestinal type gastric cancer shares many phenotypic and molecular genetic changes with colorectal cancer. In particular a progression from chronic gastritis to intestinal metaplasia, dysplasia, and finally malignant transformation is probably the sequence of gastric carcinogenesis. Somatic mutation of K-ras gene is common in colorectal cancer, being found in more than one-third of cases, but it seems to have, mostly in intestinal-type gastric cancer, a low incidence (7-20 %). The purpose of this study is to assess HER2 gene amplification and K-ras mutational status in a series of intestinal-type gastric carcinoma patients. Method: Twenty paraffin embedded gastric cancer specimens were tested for HER2 amplification by chromogenic in situ hybridization (CISH) and K-ras mutational status (codon 12 e 13) by PCR-RFLP.